The Scientific Basis of Heart Failure in the Young

描述(由申请人提供)： 心力衰竭(HF)在年轻人中是一种常见的临床实体，具有显著的发病率和死亡率，并带来大量的长期社会和经济成本。主要原因是先天性心脏病，这是最常见的出生缺陷，发病率几乎为1%。它也是潜在寿命损失年数排名第五的原因，每1000人中有2年。在美国，超过45万名儿童和100多万成年人患有先天性心脏病，这突出了它对公共健康的影响。此外，遗传性心肌病和获得性心脏病，如心肌炎，也是年轻人心力衰竭的主要原因。尽管心力衰竭在年轻人、儿童和婴儿中很重要，但与丰富的文献和成人对心力衰竭的基本了解相比，对它的研究还较少。因此，对心力衰竭儿童的治疗进展缓慢。事实上，今天大多数儿童心力衰竭治疗的新概念都是基于成人治疗策略的翻译，几乎没有临床前的证据支持他们在年轻人中的使用。然而，在心脏形态发生的分子调控以及心脏对损伤的细胞和分子反应方面的最新和令人兴奋的发现，为了解年轻人的心衰提供了新的工具。这次为期3天的会议的目标是介绍目前在儿童心力衰竭基础上的临床和基础研究，并为这一服务不足的人群规划心力衰竭研究的未来方向。会议将保持相对较小的规模(约150名与会者)，以保持与会者之间的高质量互动，并继续专注于儿童心力衰竭的科学基础。这次会议的地点是科罗拉多州的埃斯特斯公园，目的是在非正式的环境中加强这些互动，并计划于2007年秋季举行。在为期2.5天的会议中，将介绍五个主要的研究领域：1)年轻人心力衰竭的基本机制。2)基本的和新颖的HF定量工具。3)治疗心力衰竭的新方法。4)青年心力衰竭的临床科学。5)。成人先天性心脏病。本次会议有4个目标：1)加强对年轻人心力衰竭临床和基础研究的关注。2)加强基础和临床研究人员之间的合作，将重点放在年轻人的心力衰竭上。3)提高了对儿童和青壮年心力衰竭的基础和治疗的临床认识。4)增加了对新概念和新思想的理解，以了解心力衰竭及其在年轻人中的治疗。鉴于年轻人心力衰竭的不同病因，我们对指导心脏胚胎学和收缩功能的基因程序的快速发展的知识，以及迅速增长的儿童手术存活人口现在有高风险的晚发性心力衰竭，迫切需要了解年轻人的心力衰竭，以便设计新的治疗策略和合理应用现有的治疗方法。

DESCRIPTION (provided by applicant): Heart failure (HF) in the young is a common clinical entity that has significant morbidity and mortality and carries substantial long-term social and financial costs. The leading cause is congenital heart disease, which is the most common birth defect with an incidence of almost 1%. It is also the 5th ranked cause of years of potential life lost at 2 per 1000 population. Well over 450,000 children and over 1 million adults in the USA have a congenital heart defect emphasizing its impact on public health. In addition, inherited cardiomyopathies, and acquired heart disease, such as myocarditis, contribute to the overall burden of HF in the young. Despite the importance of HF in young adults, children and infants, it has been less well studied when compared with the rich literature and basic understanding of HF in adults. As a result, therapy for children with HF has advanced more slowly. Indeed, most new concepts for management of HF in children today are based on translation of adult treatment strategies with little preclinical evidence supporting their use in the young. However, recent and exciting discoveries in the molecular regulation of cardiac morphogenesis, as well as in the cellular and molecular response of the heart to injury, have provided new tools to understand HF in the young. The goal of this 3 day conference is to present current clinical and basic research on the basis of HF in children, and map out future directions in heart failure research for this underserved population. The conference will be kept relatively small (~150 participants) in order to maintain a high quality of interaction between participants, and to remain focused on the scientific basis of HF in children. The venue for this meeting, Estes Park, Colorado, is chosen to enhance these interactions in an informal setting, and is planned for the Fall of 2007. Five broad areas of research will be presented across the 2.5 days of the meeting: 1) Basic mechanisms of HF in the young. 2) Basic and novel tools for quantifying HF. 3) Novel therapies for HF. 4) Clinical science of HF in the young. 5). Adult congenital heart disease. This conference has 4 goals: 1) Increased attention to the need for clinical and basic research on HF in the young. 2) Increased collaborations between basic and clinical researchers to focus on HF in the young. 3) Improved clinical understanding of the basis for HF and its treatment in children and young adults. 4) Increased understanding of novel concepts and new ideas for understanding HF and it's treatment in the young. Given the different etiologies of HF in the young, our rapidly advancing knowledge of gene programs directing cardiac embryology and contractile function, and the rapidly growing population of children surviving surgery who now have a high risk of late onset HF, there is an urgent need to understand HF in the young in order to design new treatment strategies and rationally apply current therapies.